FDCDDQ
GERM

Federation des caisses Desjardins du Quebec’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,500
Closed -$27.3K – 2746
2024
Q2 		$27.3K Hold
1,500
– – ﹤0.01% 1533
2024
Q1 		$27.4K Hold
1,500
– – ﹤0.01% 1560
2023
Q4 		$29.2K Hold
1,500
– – ﹤0.01% 1473
2023
Q3 		$26.6K Hold
1,500
– – ﹤0.01% 1491
2023
Q2 		$30.7K Hold
1,500
– – ﹤0.01% 1470
2023
Q1 		$30.4K Hold
1,500
– – ﹤0.01% 1460
2022
Q4 		$33.4K Hold
1,500
– – ﹤0.01% 1561
2022
Q3 		$30.8K Hold
1,500
– – ﹤0.01% 1635
2022
Q2 		$34.6K Hold
1,500
– – ﹤0.01% 1615
2022
Q1 		$40.5K Hold
1,500
– – ﹤0.01% 1644
2021
Q4 		$52.9K Hold
1,500
– – ﹤0.01% 1580
2021
Q3 		$60.8K Hold
1,500
– – ﹤0.01% 1546
2021
Q2 		$59.4K Hold
1,500
– – ﹤0.01% 1553
2021
Q1 		$52.6K Hold
1,500
– – ﹤0.01% 1535
2020
Q4 		$43.2K Buy
1,500
+1,370
+1,054% +$41.7K ﹤0.01% 1532
2020
Q3 		$3.56K Buy
+130
New +$3.82K ﹤0.01% 1931

Other funds holding GERM

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's GERM Position: Q3 2024 in Review

Federation des caisses Desjardins du Quebec sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 1,500 shares — an estimated $27.3K sold.

Federation des caisses Desjardins du Quebec first reported a position in GERM in Q3 2020 and held it in 16 quarters. The position peaked at $60.8K in Q3 2021. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

  • Federation des caisses Desjardins du Quebec reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 1,500 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $27.3K.
  • Federation des caisses Desjardins du Quebec first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 16 quarters.
  • Federation des caisses Desjardins du Quebec's Amplify Treatments, Testing and Advancements ETF position peaked at $60.8K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2024, filed 13 Nov 2024.